Active Ovarian Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Ovarian Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Ovarian Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Ovarian Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Ovarian Cancer Clinical Trial FAQ

Do I need a BRCA mutation to qualify for ovarian cancer clinical trials?

No, but BRCA1/2 mutations significantly expand your options. PARP inhibitors (olaparib, niraparib, rucaparib) are approved and being studied in trials, with the strongest benefit in BRCA-mutated ovarian cancer. Patients without BRCA mutations may still qualify for PARP inhibitor trials if they have HRD (homologous recombination deficiency). Other trial types — immunotherapy, antibody-drug conjugates — do not require BRCA testing.

What is the difference between platinum-sensitive and platinum-resistant ovarian cancer for trial purposes?

Platinum-sensitive means your cancer responded to platinum-based chemotherapy (like carboplatin) and stayed in remission for at least 6 months. Platinum-resistant means the cancer returned within 6 months. Most trials specify which group they enroll. Platinum-resistant ovarian cancer is a particularly active trial area because standard options are more limited.

Are there ovarian cancer trials for fallopian tube or primary peritoneal cancer?

Yes. Clinical trials typically group high-grade serous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer together because they share the same biology. If you have one of these diagnoses, you are usually eligible for ovarian cancer trials. Trialify's search reflects this grouping.

Can I join an ovarian cancer trial after three or more prior chemotherapy regimens?

Some trials specifically enroll heavily pre-treated patients, particularly those testing antibody-drug conjugates (mirvetuximab soravtansine for folate receptor-alpha positive disease) or novel mechanisms. Other trials limit enrollment to patients with fewer prior lines. Your line of therapy is one of the first eligibility questions Trialify asks.

How do I find an ovarian cancer trial that fits my situation?

Enter your diagnosis (ovarian, fallopian tube, or primary peritoneal), platinum sensitivity, BRCA status, and location on Trialify. We search ClinicalTrials.gov, translate the eligibility criteria into yes-or-no questions, and give you a match summary to bring to your gynecologic oncologist.

Explore Other Cancer Trial Guides

• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.
• Pancreatic Cancer — Pancreatic cancer trials are at the forefront of KRAS inhibitor research, mRNA vaccines, and combination immunotherapy. Participating in a trial may give access to treatments not yet available to the general public.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.